Reader-Supported · Editorially Reviewed
§ Medication Guide

BPC-157 Peptide Therapy Online (2026)

Medication evidence and practical access information. We have no verified affiliate offer for this exact medication; the guide below is informational, not a provider availability claim.

2 studies cited
0 Verified OffersIndependent Review

We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology

No verified affiliate offer for this medication

This means we have not verified a supplied affiliate link to a page offering this exact medication—not that the medication is unavailable everywhere. We do not substitute another treatment or a general provider homepage.

BPC-157 is a synthetic peptide used in peptide therapy protocols for tissue support. It is available through select telehealth platforms with clinical oversight.

What It Is

A synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice.

Who It's For

Adults working on tissue recovery protocols under clinical guidance.

What To Expect

Most platforms offer 4-8 week protocols with clinician check-ins.

Verified Offers for bpc-157

0 verified
We do not currently have a verified affiliate destination specifically mapped to this medication. We do not substitute a general category or different-medication offer on this guide.
§ Clinical Evidence

What the Studies Actually Show

BPC-157 is not an FDA-approved drug. The published evidence is preclinical (rodent and in-vitro). We are publishing the evidence summary below so that readers can evaluate the regulatory and scientific status before deciding whether the protocol is appropriate for them.

EndpointFinding
BPC-157 — evidence base1Pre-clinical (rodent and in-vitro) studies suggest accelerated tendon, ligament, and gastrointestinal mucosal healing. No published Phase 2 or Phase 3 human trials. Not FDA-approved for any indication

BPC-157 was added to the FDA's Category 2 list in 2023, reflecting the agency's view that significant safety questions or insufficient evidence currently preclude routine compounding for human use. Some 503A pharmacies still dispense it; reputable providers disclose the regulatory status.

Sermorelin (GHRH analog) — efficacy2Modest, transient increases in IGF-1 and growth hormone pulse amplitude in adults with adult-onset growth-hormone deficiency. Body composition effects are smaller than supraphysiologic GH replacement
Sermorelin — safety2Generally well tolerated; injection-site reactions are the most common adverse event. Long-term cancer-risk data are limited
FDA regulatory status of compounded peptides3Most popular peptides (BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295) are not FDA-approved drugs. Compounded availability is governed by FDA Sections 503A/503B and the agency's Category 1/2 lists
References — Clinical Studies
  1. Sikiric P et al. — BPC-157 review, Curr Pharm Des 2018 · Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Curr Pharm Des 2018;24(18):1990–2004.
  2. Sermorelin / GHRH analogs — Endocrine 2019 · Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006;1(4):307–308.

RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.